| | hOPNc additive | hOPNex4 additive | | both combined |
|---|
| | % progr | n | % progr | n | | % progr | n |
|---|
A |
Low | 3.2 | 31 | 11.8 | 51 | L/L, L/I | 0.0 | 39 |
Intermediate | 5.7 | 35 | 5.9 | 34 | L/H, I/I | 21.1 | 38 |
High | 18.8 | 48 | 13.8 | 29 | I/H, H/H | 10.8 | 37 |
All | 10.5 | 114 | 10.5 | 114 | All | 10.5 | 114 |
B |
Low | 3 | 31 | 2 | 51 | L/L, L/I | 3 | 39 |
Intermediate | 0 | 35 | 9 | 34 | L/H, I/I | 3 | 38 |
High | 10 | 48 | 7 | 29 | I/H, H/H | 11 | 37 |
All | 5 | 114 | 5 | 114 | All | 5 | 114 |
- The pathology scores were condensed to 0,1 = low and 2,3 = high. Then, an additive score was derived as intensity plus percent positivity with low = both components low, intermediate = one low and the other high, high = both high. hOPNc additive = additive score for staining with anti-OPNc antibody F2, hOPNex4 additive = additive score for staining with anti-exon 4 antibody MAP193P. A combined score was derived from the additive scores for both antibodies, such that low/low and low/intermediate were combined to low, low/high and intermediate/intermediate were combined to intermediate, and intermediate/high and high/high are combined to high. % progr. Indicates the proportion of patients (in percent), who experienced cancer; the adjacent column (n) indicates the number of patients in the group. The bottom row is reflective of the total number of patients under study. A Progression in the ipsilateral breast. B Later cancer in the contralateral breast
